Tonix Pharmaceuticals Holding Corp. (TNXP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 5M 10M 15M FY23: 7.8M FY24: 10.1M FY25: 13.1M FY23 FY24 FY25

Gross Profit Annual

0 2.5M 5M 7.5M FY23: 3M FY24: 2.3M FY25: 6.5M FY23 FY24 FY25

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-150M -100M -50M 0 50M 100M 150M FY10: -1.9M FY11: -3.4M FY12: -6.7M FY13: -10.9M FY14: -27.7M FY15: -48.2M FY16: -39M FY17: -21.3M FY18: -26.3M FY19: -28.8M FY20: -50.5M FY21: -92.3M FY22: -112.1M FY23: -118.4M FY24: -136.7M FY25: -125.7M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-150M -100M -50M 0 50M 100M 150M FY08: -202K FY09: -221K FY10: -2M FY11: -3.5M FY12: -9.4M FY13: -10.9M FY14: -27.6M FY15: -48.1M FY16: -38.8M FY17: -21.1M FY18: -26.1M FY19: -28.6M FY20: -50.5M FY21: -92.3M FY22: -110.2M FY23: -116.7M FY24: -130M FY25: -124M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 3M 6M 9M FY23: 4.7M FY24: 7.8M FY25: 6.6M FY23 FY24 FY25

Operating Cash Flow Annual

-105M -70M -35M 0 35M 70M 105M FY10: -1.2M FY11: -2.6M FY12: -5.7M FY13: -8.5M FY14: -22.8M FY15: -42.5M FY16: -37.3M FY17: -19.1M FY18: -24M FY19: -26.7M FY20: -48.6M FY21: -75.6M FY22: -98.1M FY23: -102M FY24: -60.9M FY25: -99.8M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-150M -100M -50M 0 50M 100M 150M FY10: -1.3M FY11: -2.6M FY12: -5.7M FY13: -8.5M FY14: -23.2M FY15: -42.6M FY16: -37.4M FY17: -19.1M FY18: -24M FY19: -26.7M FY20: -57.1M FY21: -110.9M FY22: -146.2M FY23: -109.9M FY24: -61M FY25: -103.2M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 4M 8M 12M FY21: 11.4M FY22: 5.8M FY23: 7.9K FY24: 736.3K FY25: 8.5M FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-18000.00 -12000.00 -6000.00 0.00 6000.00 12000.00 18000.00 Q4 '10: -0.18 Q1 '11: -0.21 Q2 '11: -0.23 Q3 '11: -0.28 Q4 '11: -3.24 Q1 '12: -4.48 Q2 '12: -5.47 Q3 '12: -5.47 Q4 '12: -3.83 Q1 '13: -3.49 Q2 '13: -3.43 Q3 '13: -4.25 Q4 '13: -3.39 Q1 '14: -3.05 Q2 '14: -2.71 Q3 '14: -2.55 Q4 '14: -2.74 Q1 '15: -2.86 Q2 '15: -2.98 Q3 '15: -2.99 Q4 '15: -2.87 Q1 '16: -9.57 Q2 '16: -13.81 Q3 '16: -15.99 Q4 '16: -16.17 Q1 '17: -10.03 Q2 '17: -5.71 Q3 '17: -3.58 Q4 '17: -31.89 Q1 '18: -39.42 Q2 '18: -46.00 Q3 '18: -100.22 Q4 '18: -135.36 Q1 '19: -139.32 Q2 '19: -141.51 Q3 '19: -92.21 Q4 '19: -19.33 Q1 '20: -6.94 Q2 '20: 2.25 Q3 '20: 7.85 Q4 '20: -0.75 Q1 '21: -0.45 Q2 '21: -2.47 Q3 '21: -3.98 Q4 '21: -6.00 Q1 '22: -7.54 Q2 '22: -12.93 Q3 '22: -15.57 Q4 '22: -14.92 Q1 '23: -16.52 Q2 '23: -58.11 Q3 '23: -92.50 Q4 '23: -14667.85 Q1 '24: -15200.36 Q2 '24: -17071.98 Q3 '24: -17056.03 Q4 '25: -14.44 Q1 '26: -14.53 Q2 '26: -13.11 Q2 '11 Q2 '13 Q2 '15 Q2 '17 Q2 '19 Q2 '21 Q2 '23 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.